Argenx's Vyvgart Sales Outperform Expectations Across MG and CIDP Treatments.
ByAinvest
Saturday, Jan 31, 2026 4:26 am ET1min read
ARGX--
Argenx SE's Vyvgart sales outperform expectations across MG and CIDP treatments, with solid momentum expected to last through 2026. The FDA has also granted priority review for a supplemental biologics licensing application for Vyvgart to treat adults with acetylcholine receptor antibody-seronegative generalized myasthenia gravis. Argenx's other clinical products, such as empasiprubart in MMN, also have massive potential, with pivotal EMPASSION data expected in Q4 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet